Click to login and read the full article.
Don’t have access? Click here to request a demo
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600
Abstract
Longevity risk, the risk that a member of a pension plan or an annuity holder lives much longer than anticipated, can cause shortfalls in funding for writers of insurance policies, annuities, and pension benefits. Reimbursement risk, the risk faced by health benefit providers in paying for expensive new drugs, can similarly cause shortfalls for health insurance firms and other benefit providers, particularly as the costs of specialty drugs increase. These risks can be acute when scientific breakthroughs increase new drug development rates. An emerging asset class, research-backed obligations (RBOs) (Fernandez et al. 2012; Hull et al. 2019), has the potential to provide a natural hedge for a broad class of such risks. This article demonstrates how to calculate simplified, first-order portfolio-specific hedge ratios. The author presents simulation results that demonstrate the benefits of such hedges for a hypothetical health insurance portfolio facing rapid increases in reimbursement risk due to the high cost of new specialty drugs.
- © 2021 Pageant Media Ltd
Don’t have access? Click here to request a demo
Alternatively, Call a member of the team to discuss membership options
US and Overseas: +1 646-931-9045
UK: 0207 139 1600